Sign In
Buy SGEN
$228.74
+0 (+0%)
At Close: Mar 12, 2024
Seagen-Merck Bladder Cancer Treatment Shows Positive Results; Seagen Shares Jump
12:40pm, Friday, 22'nd Sep 2023
Biotechnology company Seagen Inc. (SGEN) and Tokyo-based Astellas Pharma Inc. on Friday reported positive results from a Phase 3 trial of their experimental bladder cancer medicine, Padcev, in combina
Flee to Healthcare Stocks if Recession Rears its Head?
07:04am, Wednesday, 20'th Sep 2023
If you're looking for a sector that's on sale, look to healthcare. The Health Care Select Sector SPDR Fund NYSEARCA: XLV is down 2.50% in the past month, lagging the S&P 500.
EU antitrust regulators set Oct. 19 deadline for Pfizer's Seagen deal
02:15pm, Friday, 15'th Sep 2023
Pfizer's $43 billion bid for Seagen will be decided by EU antitrust regulators by Oct. 19, a regulatory filing showed on Friday.
Zai Lab ADR surges after Seagen, Genmab release cervical cancer treatment results
08:12am, Tuesday, 05'th Sep 2023
Zai Lab Ltd.'s American depositary receipts ZLAB, +2.47% jumped 14% premarket on Tuesday after Seagen Inc. SGEN, +0.89% and Genmab A/S GMAB, +0.24% announced that Tivdak, their treatment for cervical
Genmab, Seagen say Tivdak cervical cancer trial met overall survival endpoint
05:33pm, Monday, 04'th Sep 2023
Genmab A/S , and Seagen Inc on Monday said that the Phase III trial of Tivdak in recurrent or metastatic cervical cancer patients on or after front-line therapy met its primary endpoint of overall sur
Seagen's (SGEN) Breast Cancer Study on Tuksya Combo Meets Goal
11:46am, Thursday, 17'th Aug 2023
Seagen (SGEN) announces positive top-line results from its breast cancer study evaluating Tuksya in combination with Roche's Kadcyla.
Seagen's breast cancer therapy meets main goal in late-stage study
08:34am, Wednesday, 16'th Aug 2023
Seagen said on Wednesday its breast cancer therapy in combination with Roche's Kadcyla helped extend the time patients lived without their disease progressing in a late-stage trial.
3 Pharmaceutical Stocks to Buy and Hold for the Long Haul
01:48pm, Saturday, 12'th Aug 2023
There's a reason why many investors own one or more pharmaceutical stocks. This is a $1.2 trillion industry that is essential to the quality of life for many people.
3 Healthcare Stocks With Healthy Dividends
09:05am, Thursday, 13'th Jul 2023
The stocks' shares have all declined to begin the year. Each company had a sluggish first quarter, but has a pipeline with plenty of potential.
Drugmakers' deal making will plow ahead despite antitrust scrutiny, analysts say
03:59pm, Wednesday, 12'th Jul 2023
The brisk pace of biopharmaceutical deal making seen in the first half of this year may only accelerate in the months ahead, even as regulators take a hard look at some of the bigger deals, analysts s
Best Under-the-Radar Stocks: 3 That AI Predicts Will Soar in July
12:45pm, Tuesday, 04'th Jul 2023
Under-the-radar stocks have provided compelling returns in 2023. Indeed, the rally this year has been mostly concentrated in a few key sectors, such as technology and artificial intelligence.
FTC Wants to Block the Amgen-Horizon Deal: Is Pfizer's Acquisition of Seagen at Risk, Too?
05:15am, Wednesday, 24'th May 2023
There isn't much overlap between Amgen's business and Horizons', but that isn't stopping the FTC from looking to block the deal. Pfizer has a strong oncology portfolio and is planning to acquire Seage
Is Pfizer's Seagen Deal In Jeopardy Amid Antitrust Scrutiny?
07:18am, Friday, 19'th May 2023
Pfizer Inc. NYSE: PFE continued its downward trajectory on May 17, following news that the Federal Trade Commission is seeking to block Amgen Inc.'s NASDAQ: AMGN planned acquisition of Horizon Therape
Pfizer to raise $31 billion in debt offering to fund Seagen acquisition, SEC filing shows
12:32pm, Wednesday, 17'th May 2023
The debt offering by Pfizer to buy cancer drug maker Seagen comes as Apple, Merck and T-Mobile tap the U.S. bond market ahead of the debt ceiling standoff.
Pfizer (PFE) to Raise $31B in Debt to Fund Seagen (SGEN) Deal
11:17am, Wednesday, 17'th May 2023
Pfizer (PFE) offers bonds worth $31 billion to fund its pending acquisition of cancer drugmaker, Seagen (SGEN).
